Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.
作者信息
Thakurta A, Gandhi A K, Waldman M F, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey S A, Calle Y, Chelliah R, Orlowski R Z, Madan A, Avet-Loiseau H, Chopra R
机构信息
Translational Development, Celgene Corporation, Summit, NJ, USA.
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
出版信息
Leukemia. 2014 May;28(5):1129-31. doi: 10.1038/leu.2013.315. Epub 2013 Oct 29.
Abstract
摘要
相似文献
1
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.脑桥蛋白（CRBN）和DNA损伤结合蛋白1（DDB1）基因无突变及其对免疫调节药物治疗的意义。
Leukemia. 2014 May;28(5):1129-31. doi: 10.1038/leu.2013.315. Epub 2013 Oct 29.
2
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. cereblon 是来那度胺和泊马度胺免疫调节和抗增殖活性的直接蛋白靶标。
Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3.
3
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.评估CRBN突变对骨髓瘤中免疫调节药物和新型cereblon E3连接酶调节剂反应的影响。
Blood. 2025 May 29;145(22):2630-2644. doi: 10.1182/blood.2024025861.
4
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.人源 Cereblon-DDB1-来那度胺复合物结构揭示了对沙利度胺类似物反应性的基础。
Nat Struct Mol Biol. 2014 Sep;21(9):803-9. doi: 10.1038/nsmb.2874. Epub 2014 Aug 10.
5
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Cereblon 表达是来那度胺和泊马度胺抗骨髓瘤活性所必需的。
Blood. 2011 Nov 3;118(18):4771-9. doi: 10.1182/blood-2011-05-356063. Epub 2011 Aug 22.
6
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.免疫组织化学染色评估多发性骨髓瘤细胞中 cereblon 蛋白的表达与来那度胺和沙利度胺为基础的治疗的更好反应相关，但与硼替佐米为基础的治疗无关。
Ann Hematol. 2014 Aug;93(8):1371-80. doi: 10.1007/s00277-014-2063-7. Epub 2014 Apr 1.
7
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.免疫调节药物沙利度胺、来那度胺和泊马度胺在多发性骨髓瘤中的作用机制。
Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28.
8
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).免疫调节剂来那度胺和泊马度胺通过调节 E3 泛素连接酶复合物 CRL4(CRBN)，诱导 T 细胞抑制因子 Ikaros 和 Aiolos 的降解，从而共同刺激 T 细胞。
Br J Haematol. 2014 Mar;164(6):811-21. doi: 10.1111/bjh.12708. Epub 2013 Dec 13.
9
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.多发性骨髓瘤中cereblon结合蛋白的鉴定及其与免疫调节药物治疗反应和生存的关系。
Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.
10
Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.沙利度胺通过调节 CRBN 依赖性 SALL4 降解来抑制人 iPSC 中胚层分化。
Sci Rep. 2020 Feb 18;10(1):2864. doi: 10.1038/s41598-020-59542-x.
引用本文的文献
1
Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.基因多态性对多发性骨髓瘤中蛋白酶体抑制剂和免疫调节药物治疗结果的影响
Curr Treat Options Oncol. 2025 Mar;26(3):197-212. doi: 10.1007/s11864-025-01295-8. Epub 2025 Mar 5.
2
Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes.大脑神经酰胺调节糖尿病患者肝脏中纤维母细胞生长因子23的产生。
BMB Rep. 2024 Dec;57(12):533-538. doi: 10.5483/BMBRep.2024-0068.
3
Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma.新型多氟代沙利度胺类似物在耐药性多发性骨髓瘤中的临床前评价。
Biomolecules. 2024 Jun 19;14(6):725. doi: 10.3390/biom14060725.
4
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.肿瘤和免疫细胞的药效学变化推动了伊布地骨在复发性和难治性多发性骨髓瘤中的临床作用机制。
Cell Rep Med. 2024 Jun 18;5(6):101571. doi: 10.1016/j.xcrm.2024.101571. Epub 2024 May 21.
5
Induced protein degradation for therapeutics: past, present, and future.诱导蛋白降解疗法的过去、现在和未来。
J Clin Invest. 2024 Jan 2;134(1):e175265. doi: 10.1172/JCI175265.
6
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.高水平的缺乏 IMiDs 结合域的 CRBN 异构体预示着新诊断骨髓瘤患者对基于 IMiDs 的一线治疗的反应更差。
Clin Exp Med. 2023 Dec;23(8):5227-5239. doi: 10.1007/s10238-023-01205-y. Epub 2023 Oct 10.
7
Modulation of Ca1.2 Channel Function by Interacting Proteins and Post-Translational Modifications: Implications in Cardiovascular Diseases and COVID-19.相互作用蛋白和翻译后修饰对 Ca1.2 通道功能的调节：在心血管疾病和 COVID-19 中的意义。
Handb Exp Pharmacol. 2023;279:83-103. doi: 10.1007/164_2023_636.
8
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.多发性骨髓瘤中对免疫调节药物耐药的肿瘤及微环境机制
Front Oncol. 2022 Nov 9;12:1038329. doi: 10.3389/fonc.2022.1038329. eCollection 2022.
9
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.靶向XPO1治疗复发难治性骨髓瘤的分子机制与挑战
Transl Oncol. 2022 Aug;22:101448. doi: 10.1016/j.tranon.2022.101448. Epub 2022 Jun 1.
10
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.具有高水平脑啡肽外显子10缺失剪接变体的多发性骨髓瘤患者肿瘤上调临床上可靶向的促炎细胞因子途径。
Front Genet. 2022 Feb 9;13:831779. doi: 10.3389/fgene.2022.831779. eCollection 2022.
本文引用的文献
1
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.测量 cereblon 作为来那度胺和泊马度胺反应或耐药的生物标志物，需要使用标准化试剂并了解基因复杂性。
Br J Haematol. 2014 Jan;164(2):233-44. doi: 10.1111/bjh.12622. Epub 2013 Oct 28.
2
The clinical significance of cereblon expression in multiple myeloma.cereblon 在多发性骨髓瘤中的表达的临床意义。
Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.
3
Cereblon expression in multiple myeloma: not ready for prime time.多发性骨髓瘤中的脑啡肽表达：尚未准备好进入黄金时期。
Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17.
4
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.高表达的 cereblon（CRBN）与来那度胺和地塞米松治疗多发性骨髓瘤患者的临床改善相关。
Br J Haematol. 2013 Jun;161(5):695-700. doi: 10.1111/bjh.12338. Epub 2013 Apr 9.
5
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.髓外骨髓瘤全基因组测序揭示了多药耐药性疾病中 Cereblon、蛋白酶体亚基 G2 和糖皮质激素受体的新突变。
Br J Haematol. 2013 Jun;161(5):748-751. doi: 10.1111/bjh.12291. Epub 2013 Mar 11.
6
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).CRBN基因中的A>G多态性可作为无5号染色体长臂缺失的低危/中危-1 MDS患者对来那度胺治疗反应的生物标志物。
Leukemia. 2013 Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26.
7
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.高脑红蛋白表达与接受沙利度胺维持治疗的新诊断多发性骨髓瘤患者的生存改善相关。
Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101. Epub 2012 Dec 11.
8
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. cereblon 是来那度胺和泊马度胺免疫调节和抗增殖活性的直接蛋白靶标。
Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3.
9
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Cereblon 表达是来那度胺和泊马度胺抗骨髓瘤活性所必需的。
Blood. 2011 Nov 3;118(18):4771-9. doi: 10.1182/blood-2011-05-356063. Epub 2011 Aug 22.
10
Initial genome sequencing and analysis of multiple myeloma.多发性骨髓瘤的初始基因组测序和分析。
Nature. 2011 Mar 24;471(7339):467-72. doi: 10.1038/nature09837.
Zotero 插件